Medical Food Powders in Integrative Practice: UltraInflamX, UltraClear, and Equivalent Formulations

A Clinical Review of Evidence, Mechanisms, and Practical Applications

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Direct Integrative Care

Introduction: What Are Medical Foods and Why Do They Matter?

In integrative and functional medicine, we frequently encounter patients whose nutritional needs cannot be met by conventional diet alone—particularly those managing inflammatory bowel disease (IBD), chronic gut dysfunction, toxic burden, or conditions involving systemic inflammation. This is the clinical space occupied by medical foods: a distinct FDA-defined category of products formulated for the dietary management of specific diseases under physician supervision.

The FDA defines a medical food as “a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”^1,2 This definition, codified in Section 5(b)(3) of the Orphan Drug Act (21 U.S.C. §360ee(b)(3)), distinguishes medical foods from both dietary supplements and pharmaceutical drugs. Medical foods do not require FDA premarket approval, but they do require physician oversight and must address the distinct nutritional requirements of a medically recognized condition.¹

Among the most widely used medical food powders in functional medicine practice are the Metagenics UltraInflamX and UltraClear product families, alongside Xymogen’s OptiCleanse GHI. Each addresses a different clinical axis—gut inflammation, hepatic detoxification, or combined gastrointestinal-hepatic support—and each is built on a hypoallergenic protein base with targeted bioactive compounds. This article reviews the evidence behind these formulations, verifies key claims against published literature, and offers practical clinical guidance for their use at Direct Integrative Care.

UltraInflamX Plus 360°: Targeting Gut Inflammation in IBD and Beyond

Product Overview and FDA-Labeled Indication

UltraInflamX Plus 360° (Metagenics) is classified as a medical food formulated for the dietary management of compromised gut function resulting from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.^3,4 It is provided in a vegan pea/rice protein base (13 g OptiProtein® per serving) and is designed to address the increased nutrient demands and malabsorption common in IBD patients.³

The formulation is gluten-free, dairy-free, soy-free, and low-allergenic—a critical consideration for patients with multiple food sensitivities, which are common in IBD and related conditions such as mast cell activation syndrome (MCAS).^4,5

Key Bioactive Ingredients and Evidence

CurQfen® Curcumin (Curcumagalactomannosides)

The centerpiece of UltraInflamX Plus 360° is CurQfen®, a patented curcumin-fenugreek galactomannan complex developed by Akay Natural Ingredients. The core claim—that CurQfen delivers up to 45.5-fold greater free (unconjugated) curcuminoid bioavailability compared to standard curcumin extract—is supported by a randomized, double-blind, crossover study (n=50) published in the Journal of Functional Foods in 2016 by Kumar et al.⁶ This study demonstrated that CurQfen administration provided physiologically relevant plasma concentrations of all three curcuminoids (curcumin, demethoxycurcumin, and bisdemethoxycurcumin), with over 70% of absorbed curcuminoids remaining in the unconjugated (bioactive) form.⁶

Veracity assessment: The 45.5× bioavailability claim is verified by peer-reviewed data.⁶ It is important to note that this study was conducted by researchers affiliated with Akay, the patent holder, and independently monitored by a contract research organization. The finding has been cited in subsequent published reviews and pharmacokinetic analyses. A separate RCT (n=60) published in the Journal of Clinical Psychopharmacology confirmed the safety, antioxidant efficacy, and bioavailability of CurQfen in human subjects over 30 days at 500 mg twice daily.⁷

The clinical relevance of curcumin in IBD is further supported by multiple systematic reviews and meta-analyses. A 2025 meta-analysis by Peng et al. in Explore (8 RCTs, 482 patients) found that adjunctive curcumin therapy significantly improved clinical remission in ulcerative colitis (RR = 2.33, 95% CI: 1.25–4.34, P = 0.008).⁸ A larger 2025 meta-analysis in Frontiers in Nutrition (13 placebo-controlled RCTs) confirmed a statistically significant clinical response in UC patients (RR = 2.04, P = 0.002).⁹ Curcumin’s mechanisms include inhibition of NF-κB, COX-2, TNF-α, and IL-6—pathways directly involved in mucosal inflammation.^8,9,10

Important nuance: While meta-analytic data consistently demonstrate clinical improvement, some analyses note high heterogeneity (I² = 80%) across studies, reflecting variations in curcumin preparation, dosage, and disease severity. Endoscopic remission trends favor curcumin but have not consistently reached statistical significance across all meta-analyses.^8,9 The CurQfen formulation specifically addresses one major source of this variability—poor and inconsistent bioavailability of standard curcumin.

XNT ProMatrix® Xanthohumol

UltraInflamX Plus 360° also features XNT ProMatrix®, a proprietary protein matrix technology delivering xanthohumol (XN), a prenylated chalcone derived from hops (Humulus lupulus). Xanthohumol has documented anti-inflammatory activity through suppression of NF-κB activation via inhibition of IKKβ kinase, as demonstrated in a 2018 study by Liu et al. published in Oncotarget, showing that XN ameliorated DSS-induced experimental colitis in mice through this mechanism.¹¹ A 2009 study published in Immunobiology confirmed xanthohumol’s immunomodulatory effects, including suppression of T cell proliferation and Th1 cytokine production through NF-κB inhibition.¹² A comprehensive 2026 review in Nutrients detailed XN’s regulation of Nrf2/NF-κB/mTOR/AKT pathways, supporting its anti-inflammatory and antioxidant potential.¹³

Veracity assessment: The anti-inflammatory properties of xanthohumol are well-supported by preclinical research, including colitis-specific animal models. However, human clinical trial data for xanthohumol remain limited compared to curcumin. The evidence base for xanthohumol is best characterized as strong preclinical support with early-stage clinical translation.^11,12,13

Additional Formula Components

UltraInflamX Plus 360° provides several additional nutrients with mechanistic relevance to gut inflammatory conditions: L-glutamine (750 mg/serving), which serves as the primary fuel for intestinal epithelial cells and supports tight junction integrity; glycine (540 mg) and L-arginine (1,080 mg), both supporting mucosal healing and nitrogen balance; methylated B vitamins (5-MTHF and methylcobalamin), important for patients with MTHFR polymorphisms affecting methylation pathways; vitamin D (500 IU) and vitamin C (160 mg), both of which support immune modulation; and ginger root extract (100 mg), standardized to 5% total pungent compounds, providing additional gastrointestinal support.^3,4

Standard dosing: 2 scoops (approximately 46 g) blended into 8 fluid ounces of chilled water or juice, taken twice daily, or as directed by the supervising physician.³

The UltraClear Family: Hepatic Detoxification Support

Clinical Rationale

While UltraInflamX targets the gut inflammatory axis, the UltraClear product family (Metagenics) addresses a complementary clinical need: supporting the hepatic biotransformation (detoxification) pathways that process and clear endogenous waste products, environmental toxins, and metabolic byproducts. In functional medicine, impaired Phase I and Phase II hepatic detoxification is recognized as a contributor to systemic inflammation, chemical sensitivity, fatigue, and neurocognitive symptoms.^14,15

The concept of nutritional support for hepatic detoxification is grounded in the biochemistry of cytochrome P450 enzymes (Phase I) and conjugation reactions including glucuronidation, sulfation, glutathione conjugation, and amino acid conjugation (Phase II). Each of these pathways requires specific cofactors—B vitamins, amino acids (glycine, taurine, cysteine, methionine), antioxidants (vitamins C and E, beta-carotene), and phytonutrients (green tea catechins)—that are provided in the UltraClear formulations.^14,15,16

Product Variants and Differentiation

UltraClear Plus: Phase II Detoxification

UltraClear® Plus Detox Powder is formulated to provide enhanced support for Phase II hepatic detoxification, specifically targeting conjugation reactions. It features glycine and L-cysteine as direct Phase II conjugation substrates, green tea catechins as antioxidants that protect against reactive intermediates generated during Phase I metabolism, and beta-carotene for additional antioxidant support. The rice protein base (OptiProtein®) was selected for its low-allergenic profile and has been suggested to benefit liver function during metabolic detoxification.^15,16

The product label identifies it as a medical food for patients who may benefit from additional nutritional support for Phase II hepatic detoxification function, with a specific indication referencing chronic fatigue syndrome.¹⁵

UltraClear Renew: Comprehensive Detoxification and Heavy Metal Support

UltraClear® Renew is the most comprehensive formulation in the UltraClear line, designed to support Phase I, Phase II, and Phase III detoxification simultaneously. It features xanthohumol (as XNT ProMatrix®), Brassinase™ broccoli sprout and floret powder, N-acetyl-L-cysteine (NAC), and prune and pomegranate extracts. Additional Phase II support is provided by glycine and magnesium sulfate. This variant is specifically marketed for patients who may benefit from support for detoxification function and includes a specific reference to altered pain signaling and neuromuscular function in fibromyalgia.^17,18

Veracity assessment: Preliminary clinical data from Metagenics references a small study in fibromyalgia patients with dental amalgams, in which UltraClear Renew administration was associated with significant decreases in Fibromyalgia Impact Questionnaire (FIQ) scores, including pain and stiffness, alongside increased excretion of certain heavy metals including mercury. This research is characterized as “preliminary” by the manufacturer and involved a small patient sample. While the mechanistic rationale for supporting detoxification cofactors is biochemically sound, larger controlled trials have not been published for this specific product.^17,18

Sensitive Patient Considerations

All UltraClear variants carry manufacturer instructions advising clinicians to start sensitive patients at half to one scoop (rather than the standard two scoops) with 4–5 ounces of water during the first 3–4 days before advancing to the full dose.¹⁶ This “start low, go slow” approach is particularly relevant for patients with chemical sensitivities, mold-related illness (CIRS), mast cell activation syndrome, or a history of paradoxical reactions to supplements.

Xymogen OptiCleanse GHI: A Comparable Alternative

Xymogen’s OptiCleanse GHI occupies a clinical niche comparable to the combined functions of UltraInflamX and UltraClear, providing simultaneous gastrointestinal and hepatic support in a single formulation. It is classified as a comprehensive, low-allergy-potential dietary supplement (not formally labeled as a medical food) designed to support gastrointestinal function and balanced detoxification.^19,20

Formulation and Key Ingredients

OptiCleanse GHI is built on VegaPro™, Xymogen’s proprietary amino acid and pea/rice protein blend, with Aminogen® added to facilitate protein absorption. It provides a comprehensive nutrient profile including activated B vitamins (Quatrefolic® methylfolate and methylcobalamin), phytonutrients, and mineral amino acid chelates. In conjunction with a modified elimination diet, OptiCleanse GHI is designed to address both GI function and hepatic detoxification, as well as eicosanoid balance and cytokine metabolism.^19,20

Notably, OptiCleanse GHI includes several bioactive compounds also found in the Metagenics product lines: quercetin, curcumin, rutin, and bioflavonoids for antioxidant and cytokine-modulating activity; green tea catechins and watercress for Phase I/II detoxification support; ginger root for digestive function and anti-inflammatory effects; taurine, glycine, and L-glutamine for hepatic conjugation and gut barrier repair; and MeadowPure™ flax for lignans, essential fatty acids, and soluble fiber.^20,21

The product is sugar-free and stevia-free, free from gluten, dairy, soy, egg, shellfish, peanuts, tree nuts, and GMO-derived ingredients, and is available exclusively through licensed Xymogen practitioners.¹⁹

How OptiCleanse GHI Compares to Metagenics Products

A Practical Clinical Framework

At Direct Integrative Care, medical food powders are incorporated into individualized protocols based on the patient’s primary presentation. In clinical practice, the choice among these products depends on which axis is driving the patient’s symptoms.

For patients whose primary issue is gut inflammation—active IBD, MCAS with predominant GI involvement, or post-infectious gut dysfunction—UltraInflamX Plus 360° is generally the first-line medical food, leveraging the bioavailable CurQfen® curcumin and xanthohumol to address mucosal NF-κB-driven inflammation. For patients whose primary driver is toxic burden—environmental chemical exposure, mold-related illness, heavy metal accumulation, or chronic fatigue with suspected impaired detoxification—the UltraClear product line (particularly UltraClear Renew for comprehensive Phase I/II/III support) is preferred. OptiCleanse GHI serves as an effective option when the clinical picture involves both gastrointestinal dysfunction and detoxification needs simultaneously, or when a single product is preferred for protocol simplicity and cost considerations.

All three product families are used in conjunction with a modified elimination diet to reduce the dietary antigen load while the medical food provides targeted nutritional support. For highly sensitive patients—common in MCAS, mold illness, and chemical sensitivity populations—the protocol begins at reduced dosing (one-quarter to one-half the recommended serving) for the first three to four days before titrating to the full dose.

Veracity Summary: What the Evidence Supports and Where Gaps Remain

Well-supported by peer-reviewed evidence: The CurQfen® 45.5× bioavailability claim (RCT, n=50, published in Journal of Functional Foods); curcumin efficacy in UC clinical remission (multiple meta-analyses of RCTs, including 2025 publications with 482+ patients); xanthohumol’s NF-κB and IKKβ inhibition in colitis models (published preclinical research); the FDA definition and regulatory framework for medical foods (Orphan Drug Act, 21 C.F.R. §101.9(j)(8)); and the biochemical basis for Phase I/II/III hepatic detoxification cofactor requirements.^1,2,6,8,9,11

Supported by preliminary or mechanistic evidence: UltraClear Renew’s effect on FIQ scores in fibromyalgia (manufacturer-referenced small study, not independently replicated); xanthohumol’s clinical translation from preclinical to human data (limited human trials); the specific application of these medical foods to MCAS (evidence-based extrapolation from IBD and gut permeability research, not disease-specific RCTs).^13,17,18

Important limitations: No large-scale RCTs exist for UltraInflamX Plus 360° as a complete formulation (evidence is for individual ingredients, particularly curcumin). OptiCleanse GHI is classified as a dietary supplement rather than a medical food and does not carry the same medical food regulatory status. The curcumin meta-analytic literature, while consistently positive, shows high heterogeneity across studies.^8,9

The Bottom Line

Medical food powders represent a clinically meaningful tool in integrative practice—not as replacements for conventional therapy, but as nutritionally targeted adjuncts that address the specific metabolic and inflammatory demands of gut and detoxification-related conditions. The evidence base for their key bioactive ingredients, particularly curcumin, continues to grow through well-designed RCTs and meta-analyses. Practitioners and patients at Direct Integrative Care benefit from these formulations as part of individualized, root-cause-directed protocols guided by the best available evidence.

These products are intended for use under physician supervision. If you are managing IBD, chronic gut dysfunction, toxic burden, or related conditions and would like to explore whether a medical food protocol is appropriate for your situation, I welcome you to schedule a consultation through Direct Integrative Care.

References

1. U.S. Food and Drug Administration. Frequently Asked Questions About Medical Foods; Third Edition. Section 5(b)(3) of the Orphan Drug Act (21 U.S.C. 360ee(b)(3)). Available at: https://www.fda.gov/food/guidance-documents-regulatory-information-topic-food-and-dietary-supplements/medical-foods-guidance-documents-regulatory-information

2. U.S. Food and Drug Administration. Medical Foods Guidance Documents and Regulatory Information. 21 CFR 101.9(j)(8). Updated March 2023.

3. Metagenics, Inc. UltraInflamX Plus 360° Product Label and Program Guide. Available at: https://www.metagenics.com/en-us/product/ultrainflamx-plus-360

4. Metagenics, Inc. UltraInflamX Plus 360° Product Monograph. Formulated for the dietary management of compromised gut function resulting from IBD.

5. BodyLogicMD. UltraInflamX Plus 360° Product Description. Available at: https://www.bodylogicmd.com/shop/ultrainflamx-plus-360/

6. Kumar D, Jacob D, Subash PS, et al. Enhanced bioavailability and relative distribution of free (unconjugated) curcuminoids following the oral administration of a food-grade formulation with fenugreek dietary fibre: A randomised double-blind crossover study. J Funct Foods. 2016;22:578–587. doi:10.1016/j.jff.2016.01.039

7. Pandaran Sudheeran S, Jacob D, Natinga Mulakal J, et al. Safety, tolerance, and enhanced efficacy of a bioavailable formulation of curcumin with fenugreek dietary fiber on occupational stress: A randomized, double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2016;36(3):236–243. doi:10.1097/JCP.0000000000000508. PMID: 27043120

8. Peng Z, Li D, Wu N, et al. Safety and efficacy of curcumin in the treatment of ulcerative colitis: An updated systematic review and meta-analysis of randomized controlled trials. Explore (NY). 2025;21(1):103083. doi:10.1016/j.explore.2024.103083. PMID: 39612780

9. Wang S, Sun H, Wang Q, Xiao H. Curcumin for the clinical treatment of inflammatory bowel diseases: A systematic review and meta-analysis of placebo-controlled randomized clinical trials. Front Nutr. 2025;12. doi:10.3389/fnut.2025.1490667. PMID: 40196017

10. Iqbal U, Anwar H, Quadri AA. Use of curcumin in achieving clinical and endoscopic remission in ulcerative colitis: A systematic review and meta-analysis. Am J Med Sci. 2018;356(4):350–356. doi:10.1016/j.amjms.2018.06.023

11. Liu X, et al. Xanthohumol prevents dextran sulfate sodium-induced colitis via inhibition of IKKβ/NF-κB signaling in mice. Oncotarget. 2018;9(25):17821–17834. PMC5787519

12. Gao X, et al. Immunomodulatory activity of xanthohumol: Inhibition of T cell proliferation, cell-mediated cytotoxicity and Th1 cytokine production through suppression of NF-κB. Immunobiology. 2009;214(6):491–497.

13. Nunes S, Ferreirinha P, Paiva I, et al. Xanthohumol: Mechanistic actions and emerging evidence as a multi-target natural nutraceutical. Nutrients. 2026;18(3):520. doi:10.3390/nu18030520

14. Bland JS, et al. Medical food composition for metabolic detoxification. U.S. Patent Nos. 5,629,023 and 5,637,324.

15. National Nutrition Canada. UltraClear Plus by Metagenics Product Information. Available at: https://www.nationalnutrition.ca/metagenics-ultra-clear-plus-vanilla-882g.html

16. Metagenics, Inc. UltraClear Plus Detox Powder Product Label. Available at: IPM Supplements Product Listing.

17. Metagenics, Inc. UltraClear Renew Detox Powder Product Label. Available at: https://www.metagenics.com/en-us/product/ultraclear-renew-detox-powder

18. Apex Pharmacy and Nutrition Center. UltraClear Renew Product Information: Preliminary fibromyalgia research reference. Available at: https://www.theapexstore.com/metagenics-ultraclear-renewtrade-medical-food-274-oz.html

19. Xymogen, Inc. OptiCleanse GHI Product Information. Available at: https://www.xymogen.com/product/opticleanse-ghi-creamy-chocolate-sugar-stevia-free-10-servings

20. Alive and Well Shop. Xymogen OptiCleanse GHI Product Description and Ingredient Analysis. Available at: https://shop.aliveandwell.health/products/opticleanse-ghi

21. AcuAtlanta. OptiCleanse GHI: What Is It and What Are Its Benefits? Published October 2024. Available at: https://acuatlanta.net/blog/opticleanse-ghi-what-is-it-and-what-are-its-benefits/

22. Fullscript. Metagenics Detoxification Support Protocol. Published March 2025. Available at: https://fullscript.com/protocol/metagenics-detoxification-support

23. Lee DH, et al. Differential anti-inflammatory pathway by xanthohumol in IFN-γ and LPS-activated macrophages. Int Immunopharmacol. 2008;8(4):567–573. doi:10.1016/j.intimp.2008.01.003

About Dr. Kim

Dr. Yoon Hang “John” Kim is a board-certified Preventive Medicine physician and Integrative & Functional Medicine specialist with over 20 years of clinical experience. A fellowship-trained graduate of the University of Arizona Center for Integrative Medicine under Dr. Andrew Weil, he holds additional certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of three books and over 20 published articles on these topics.

Professional: www.yoonhangkim.com

Clinical: www.directintegrativecare.com